Eledon Pharmaceuticals (ELDN) Competitors $4.36 +0.14 (+3.32%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ELDN vs. BCYC, AVDL, SEPN, COLL, BCAX, ZYME, GYRE, PSTX, PAHC, and COGTShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Septerna (SEPN), Collegium Pharmaceutical (COLL), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Bicycle Therapeutics Avadel Pharmaceuticals Septerna Collegium Pharmaceutical Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Cogent Biosciences Eledon Pharmaceuticals (NASDAQ:ELDN) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Which has stronger valuation and earnings, ELDN or BCYC? Eledon Pharmaceuticals has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$116.54M-$2.01-2.17Bicycle Therapeutics$36.90M27.47-$180.66M-$3.29-4.46 Do analysts recommend ELDN or BCYC? Eledon Pharmaceuticals presently has a consensus target price of $16.00, indicating a potential upside of 266.97%. Bicycle Therapeutics has a consensus target price of $35.25, indicating a potential upside of 140.12%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has more volatility & risk, ELDN or BCYC? Eledon Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Does the media favor ELDN or BCYC? In the previous week, Bicycle Therapeutics had 28 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 29 mentions for Bicycle Therapeutics and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.86 beat Bicycle Therapeutics' score of 0.55 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicycle Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ELDN or BCYC? 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 11.7% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ELDN or BCYC? Bicycle Therapeutics received 109 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 70.10% of users gave Bicycle Therapeutics an outperform vote. CompanyUnderperformOutperformEledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Bicycle TherapeuticsOutperform Votes13670.10% Underperform Votes5829.90% Is ELDN or BCYC more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -189.99% -28.17% Bicycle Therapeutics -450.64%-27.35%-20.81% SummaryEledon Pharmaceuticals beats Bicycle Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.46M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-2.1710.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book14.535.094.784.78Net Income-$116.54M$151.83M$120.23M$225.60M7 Day Performance-0.46%-2.13%-1.92%-1.23%1 Month Performance7.13%-3.10%11.49%3.36%1 Year Performance194.59%11.54%30.57%16.60% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.9252 of 5 stars$4.36+3.3%$16.00+267.0%+196.6%$260.46MN/A-2.1710Positive NewsHigh Trading VolumeBCYCBicycle Therapeutics3.6062 of 5 stars$15.31+10.9%$36.00+135.1%-18.8%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6583 of 5 stars$10.90+4.9%$24.43+124.1%-24.0%$1.05B$138.16M-13.15154Positive NewsSEPNSepterna2.2189 of 5 stars$22.24-0.7%$43.67+96.3%N/A$987.46MN/A0.00N/ACOLLCollegium Pharmaceutical3.8414 of 5 stars$30.55+1.5%$42.60+39.4%-0.4%$985.24M$599.25M12.97210News CoveragePositive NewsBCAXBicara TherapeuticsN/A$17.57+0.4%$43.00+144.7%N/A$956.09MN/A0.0032News CoverageGap DownZYMEZymeworks2.8055 of 5 stars$13.80+9.7%$18.83+36.5%+52.5%$950.54M$76.01M-9.25290Analyst ForecastNews CoverageGap DownGYREGyre Therapeutics0.6053 of 5 stars$10.12+5.0%N/A-61.2%$946.43M$105.03M0.0040News CoveragePositive NewsPSTXPoseida Therapeutics3.7522 of 5 stars$9.52+0.1%$9.50-0.2%+193.5%$930.77M$64.70M-15.10260Positive NewsPAHCPhibro Animal Health4.1314 of 5 stars$22.92+1.1%$19.00-17.1%+89.6%$928.33M$1.05B52.561,940Analyst ForecastCOGTCogent Biosciences1.9533 of 5 stars$8.35+2.5%$14.83+77.6%+51.9%$922.34MN/A-3.2980 Related Companies and Tools Related Companies BCYC Competitors AVDL Competitors SEPN Competitors COLL Competitors BCAX Competitors ZYME Competitors GYRE Competitors PSTX Competitors PAHC Competitors COGT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELDN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
